Log In
BCIQ
Print this Print this
 

VR506

  Manage Alerts
Collapse Summary General Information
Company Vectura Group plc
DescriptionInhaled corticosteroid
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAsthma
Indication DetailsTreat asthma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$12.0M

$4.0M

$8.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/30/2014

$12.0M

$4.0M

$8.0M

Get a free BioCentury trial today